{"entity":{"id":"nct05710848","kind":"trial","name":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","aka":[],"tldr":"A phase 1/2 trial of STM-416 in bladder & urothelial cancer, run by SURGE Therapeutics, now recruiting.","summary":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer is a phase 1/2 interventional study registered as NCT05710848 by SURGE Therapeutics, with 75 participants planned, started 2023-07-11 and due to reach its primary completion in 2026-05. Interventions recorded: STM-416.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05710848","url":"https://clinicaltrials.gov/study/NCT05710848"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05710848","phase":"1/2","setting":"A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer","sponsor":"SURGE Therapeutics","enrolled":75,"outcomes":[]},"route":"/trials/nct05710848/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}]}}